181 related articles for article (PubMed ID: 32168037)
1. Management of residual disease after chemotherapy in germ cell tumors.
King J; Adra N; Einhorn LH
Curr Opin Oncol; 2020 May; 32(3):250-255. PubMed ID: 32168037
[TBL] [Abstract][Full Text] [Related]
2. [Retroperitoneal residual tumor resection after chemotherapy of malignant testicular cancers].
Albers P
Aktuelle Urol; 2012 May; 43(3):197-206. PubMed ID: 22639031
[No Abstract] [Full Text] [Related]
3. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
4. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
5. [The surgery after. . . retroperitoneal lymph node dissection and surgery of the residual masses after chemotherapy for advanced testicular cancer].
Guillemin F; Belinga JF; Marchal F; Rauch P; Verhaeghe JL
Bull Cancer; 2011 Jan; 98(1):43-51. PubMed ID: 21300599
[TBL] [Abstract][Full Text] [Related]
6. [In which marker-positive patients with germ cell tumors is residual tumor resection of value?].
Weinknecht S; Hartmann M; Weissbach L
Urologe A; 1998 Nov; 37(6):621-4. PubMed ID: 9887490
[TBL] [Abstract][Full Text] [Related]
7. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
8. Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.
Ghodoussipour S; Daneshmand S
Urol Clin North Am; 2019 Aug; 46(3):389-398. PubMed ID: 31277733
[TBL] [Abstract][Full Text] [Related]
9. [Management of residual masses of testis germ cell tumors].
Tremeau L; Mottet N
Bull Cancer; 2020 Feb; 107(2):215-223. PubMed ID: 31882267
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
Balzer BL; Ulbright TM
Am J Surg Pathol; 2006 Jul; 30(7):858-65. PubMed ID: 16819328
[TBL] [Abstract][Full Text] [Related]
11. [Testis germ cell tumours: which chemotherapy, for which patients?].
Fléchon A; Droz JP
Ann Urol (Paris); 2007 Apr; 41(2):56-67. PubMed ID: 17486913
[TBL] [Abstract][Full Text] [Related]
12. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
13. Tumors of the Testis: Morphologic Features and Molecular Alterations.
Howitt BE; Berney DM
Surg Pathol Clin; 2015 Dec; 8(4):687-716. PubMed ID: 26612222
[TBL] [Abstract][Full Text] [Related]
14. Pearls and perils in the management of germ cell tumors.
Wei CX; Einhorn LH; Adra N
Curr Opin Oncol; 2021 May; 33(3):206-211. PubMed ID: 33577208
[TBL] [Abstract][Full Text] [Related]
15. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
16. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
17. Current Management of Disseminated Germ Cell Tumors.
Lavoie JM; Kollmannsberger CK
Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732
[TBL] [Abstract][Full Text] [Related]
18. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
19. Postchemotherapy residual masses in germ cell tumor patients: our experience.
Morelli F; Tozzi L; Setola P; Bisceglia M; Barbini VR; Maiello E
Ann Oncol; 2006 Jun; 17 Suppl 7():vii132-6. PubMed ID: 16760276
[TBL] [Abstract][Full Text] [Related]
20. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
